Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares")

Q: What does CUSIP 55234L105 represent in this 13F holders report?

CUSIP 55234L105 is the security identifier for 55234L105 - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares") used to aggregate holder disclosures.

Q: How many institutions held 55234L105 - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares") in Q1 2024?

2 institutional investors reported 55234L105 - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares") for Q1 2024. Use the holders table for investor-level position and value details.

CUSIP: 55234L105

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class: Equity / Common Stock, $0.001 par value per share (the "Shares")
Total 13F shares: 278,099
Share change: +58,122
Total reported value: $1,729,776
Price per share: $6.22
Number of holders: 2
Value change: +$361,519
Number of buys: 2

Security key

55234L105

Report period

Q1 2024

Institutions

Top holders

55234L105 full security history Newer quarter: Q2 2024 Previous quarter: Q4 2023 Lyra Therapeutics, Inc. SEC filings

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 55234L105

Newer quarter: Q2 2024 Previous quarter: Q4 2023

Recent filing periods:

Q3 2024 Q2 2024 Q1 2024 Q4 2023

Top shareholders of 55234L105 - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
CITADEL ADVISORS LLC	13F	Company	— class O/S missing	2,861,255	$14,992,977	—	31 Dec 2023	13F
BlackRock Finance, Inc.	13F	Company	— class O/S missing	110,797	$580,577	—	31 Dec 2023	13F
STATE STREET CORP	13F	Company	— class O/S missing	109,180	$572,103	—	31 Dec 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	— class O/S missing	43,900	$230	—	31 Dec 2023	13F

Institutional Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares") as of Q1 2024

As of 31 Mar 2024, Lyra Therapeutics, Inc. - Common Stock, $0.001 par value per share (the "Shares") was held by 2 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 278,099 shares. The largest 4 holders included CITADEL ADVISORS LLC, BlackRock Inc., STATE STREET CORP, and RENAISSANCE TECHNOLOGIES LLC. This page lists 4 institutional shareholders reporting positions in this security for the Q1 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 holders

Q1 2024 holders

Holder diff

Investor	Q4 2023 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q4 2023 Value $	Q1 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.